A study to evaluate the efficacy, safety, and tolerability of Olpasiran (AMG890, a small interfering RNA) in subjects with elevated lipoprotein(a). PUBLICATIONS Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. Am Heart J. 2022 May 16;251:61-69. OCEAN(a)-DOSE on ClinicalTrials.gov Contact Us about OCEAN(a)-DOSE